Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA: 600436)

Zhangzhou Pientzehuang Pharmaceutical., Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,270	1,159	2,496	7,097	5,168	4,263
Short-Term Investments	-	9,014	6,202	-	-	-
Trading Asset Securities	-	-	-	8.8	0.01	0.02
Cash & Short-Term Investments	3,270	10,173	8,698	7,106	5,168	4,263
Cash Growth	24.17%	16.95%	22.42%	37.48%	21.23%	53.00%
Accounts Receivable	868.01	1,021	859.49	673.3	574.34	486.93
Other Receivables	68.28	65.15	107.94	134.95	70.11	208.5
Receivables	936.29	1,086	967.43	808.25	644.45	695.43
Inventory	4,566	3,379	2,628	2,438	2,191	2,097
Prepaid Expenses	-	14.05	4.55	20.68	-	24.54
Other Current Assets	7,072	447.9	406.61	261.36	292.18	271.95
Total Current Assets	15,845	15,100	12,705	10,633	8,296	7,352
Property, Plant & Equipment	697.19	614.62	465.62	400.14	274.96	253.4
Long-Term Investments	756.25	631.98	673.7	799.87	979.2	896.2
Other Intangible Assets	276.83	291.09	319.37	220.96	259.38	155.66
Long-Term Deferred Tax Assets	200.72	187.31	167.26	166.98	85.41	76.2
Long-Term Deferred Charges	24.6	29.99	37.65	44.19	49.42	32.83
Other Long-Term Assets	187.27	225.4	235.41	255.59	261.16	44.21
Total Assets	17,987	17,080	14,604	12,521	10,206	8,811
Accounts Payable	417.9	667.92	464.9	386.99	239.94	260.56
Accrued Expenses	151.5	685.98	345.39	342.14	139.24	249.14
Short-Term Debt	983.19	989.93	970.96	775.79	718.38	696.85
Current Portion of Long-Term Debt	28.1	1.87	-	-	-	-
Current Portion of Leases	-	31.86	29.21	22.75	-	-
Current Income Taxes Payable	270.18	142.65	72.93	108.96	77.56	220.48
Current Unearned Revenue	65.83	237.1	468.57	326.56	283.75	201.76
Other Current Liabilities	1,180	125.8	158.22	173.9	341.46	118.21
Total Current Liabilities	3,096	2,883	2,510	2,137	1,800	1,747
Long-Term Debt	51.42	35.44	-	-	-	-
Long-Term Leases	111	107.29	108.8	86.67	-	-
Long-Term Unearned Revenue	27.18	17.67	17.01	20.24	14.68	14.72
Long-Term Deferred Tax Liabilities	28.8	30.02	61.09	74.52	47.47	47.83
Other Long-Term Liabilities	37.11	51.35	48.54	32.88	57.09	2.54
Total Liabilities	3,386	3,160	2,780	2,384	1,949	1,841
Common Stock	603.32	603.32	603.32	603.32	603.32	603.32
Additional Paid-In Capital	1,095	1,095	1,094	1,086	1,085	1,084
Retained Earnings	12,195	11,602	9,559	7,816	5,862	4,686
Comprehensive Income & Other	127.68	76.6	74.41	200.05	311.57	257.5
Total Common Equity	14,021	13,376	11,330	9,705	7,862	6,631
Minority Interest	580.2	544.17	493.97	432.07	394.39	338.41
Shareholders' Equity	14,602	13,920	11,824	10,138	8,257	6,970
Total Liabilities & Equity	17,987	17,080	14,604	12,521	10,206	8,811
Total Debt	1,174	1,166	1,109	885.21	718.38	696.85
Net Cash (Debt)	2,096	9,007	7,589	6,220	4,450	3,567
Net Cash Growth	25.91%	18.67%	22.01%	39.78%	24.77%	63.08%
Net Cash Per Share	3.47	14.94	12.59	10.31	7.37	5.92
Filing Date Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Total Common Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Working Capital	12,748	12,217	10,195	8,496	6,496	5,605
Book Value Per Share	23.24	22.17	18.78	16.09	13.03	10.99
Tangible Book Value	13,744	13,085	11,011	9,484	7,603	6,476
Tangible Book Value Per Share	22.78	21.69	18.25	15.72	12.60	10.73
Buildings	-	400.13	331.45	332.55	331.29	292.92
Machinery	-	345.33	324.4	300.25	263.39	222.81
Construction In Progress	-	157.19	60.78	14.94	1.03	11.16

Source: S&P Capital IQ. Standard template. Financial Sources.